Asset Management One Co. Ltd. Reduces Stock Holdings in Zoetis Inc. $ZTS

Key Points

• Asset Management One Co. Ltd. reduced its stock holdings in Zoetis Inc. by 1.9%, owning 207,966 shares valued at $32.4 million after selling 3,976 shares in Q2.
• Zoetis reported a quarterly EPS of $1.76, exceeding analyst estimates, with a 4.2% year-over-year revenue increase during the same period.
• The company declared a quarterly dividend of $0.50, resulting in a 1.4% dividend yield, with a payment date set for December 2nd.

Asset Management One Co. Ltd. decreased its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 1.9% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 207,966 shares of the company's stock after selling 3,976 shares during the quarter. Asset Management One Co. Ltd.'s holdings in Zoetis were worth $32,432,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Nova Wealth Management Inc. purchased a new stake in Zoetis in the first quarter worth $25,000. 1248 Management LLC purchased a new stake in Zoetis in the first quarter worth $27,000. Saudi Central Bank purchased a new stake in Zoetis in the first quarter worth $29,000. REAP Financial Group LLC lifted its stake in Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company's stock worth $31,000 after acquiring an additional 131 shares during the period. Finally, Cornerstone Planning Group LLC lifted its stake in Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock worth $30,000 after acquiring an additional 88 shares during the period. Hedge funds and other institutional investors own 92.80% of the company's stock.

Zoetis Price Performance

ZTS opened at $146.14 on Friday. The stock has a 50-day moving average price of $148.18 and a 200-day moving average price of $153.50. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The firm has a market cap of $64.77 billion, a PE ratio of 25.15, a P/E/G ratio of 2.35 and a beta of 0.90. Zoetis Inc. has a 1 year low of $139.34 and a 1 year high of $184.40.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. The firm had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.Zoetis's quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.4%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis's payout ratio is currently 34.42%.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. Weiss Ratings reissued a "hold (c-)" rating on shares of Zoetis in a research report on Friday. Leerink Partnrs lowered Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Piper Sandler raised their price objective on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research report on Monday, August 11th. UBS Group lowered their price objective on Zoetis from $165.00 to $158.00 and set a "neutral" rating for the company in a research report on Monday. Finally, Leerink Partners lowered Zoetis from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Four research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $195.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.